Your session is about to expire
← Back to Search
Decision Support Interventions for Atrial Fibrillation (RED-AF Trial)
RED-AF Trial Summary
This trial will compare how well two different aids work in helping people with atrial fibrillation make decisions about their care, and whether adopting the aid leads to better health outcomes.
RED-AF Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRED-AF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RED-AF Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- All healthcare providers responsible for giving anticoagulation treatment to eligible patients with atrial fibrillation at the participating sites can participate.I have trouble thinking, remembering, or have issues with my senses.You are aware that you have atrial fibrillation.You have a higher risk of blood clotting based on certain health factors.My doctor thinks I shouldn't start or stop blood thinners.I am 18 or older with Atrial Fibrillation.
Frequently Asked Questions
How many participants are in the current experimental treatment?
"Confirmed. The trial's information on clinicaltrials.gov reveals that it is actively searching for participants. Initially posted in December 2020, with the latest update from May 2022, 1200 patients need to be recruited across 6 medical locations."
Is enrollment still available for this trial?
"The clinicaltrials.gov page for this experiment indicates that recruitment is currently in progress. This medical trial was first listed on December 16th 2020 and underwent its most recent edit on May 19th 2022."
In what number of healthcare facilities is this clinical trial currently taking place?
"The Mayo Clinic in Rochester, Minnesota and the University of Alabama at Birmingham in Birmingham, Alabama are two major sites for this trial. Additionally, Northwestern University in Chicago, Illinois is also included amongst 6 other locations offering participation."
What is the goal of this clinical investigation?
"This study's primary measure, to be determined through post-encounter surveys within a week of the visit, is Decisional Conflict Scale. Secondary outcomes are Preparation for Decision Making assessed by a validated Likert scale from 1 (not at all) to 5 (a great deal), Anticoagulation Adherence 1 measured via a 100 point Visual Analogue Scale from 0% (no medication taken as prescribed) to 100%, and finally Self Reported 7 day pill taking behaviour with questions about missed doses due side effects or costs affecting dosage adherence."
Share this study with friends
Copy Link
Messenger